143 related articles for article (PubMed ID: 29450445)
21. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
[No Abstract] [Full Text] [Related]
22. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
23. [Current therapeutic indications of thalidomide and lenalidomide].
Ordi-Ros J; Cosiglio FJ
Med Clin (Barc); 2014 Apr; 142(8):360-4. PubMed ID: 23830554
[TBL] [Abstract][Full Text] [Related]
24. [Failure of thalidomide treatment in a case of leprous erythema multiforme].
Duperrat B; Puissant A; Pringuet R; Revuz J; Lauret P; Ghezzi
Bull Soc Fr Dermatol Syphiligr; 1968; 75(6):736-7. PubMed ID: 5712975
[No Abstract] [Full Text] [Related]
25. The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
Brioli A; Melchor L; Titley I; Vijayaraghavan G; Stephens C; Zeisig A; Pawlyn C; Cavo M; Morilla R; Davies FE; Morgan GJ
Leuk Lymphoma; 2014 Nov; 55(11):2665-8. PubMed ID: 24660850
[No Abstract] [Full Text] [Related]
26. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Barley K; He W; Agarwal S; Jagannath S; Chari A
Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
28. [Thalidomide in acute symptoms in leprosy (erythema nodosum or multiforme)].
Opromolla DV; Lima LS; Marques MB
Hospital (Rio J); 1966 Apr; 69(4):827-44. PubMed ID: 5327229
[No Abstract] [Full Text] [Related]
29. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.
Castaneda CP; Brandenburg NA; Bwire R; Burton GH; Zeldis JB
J Clin Oncol; 2009 Jan; 27(1):156-7. PubMed ID: 19047275
[No Abstract] [Full Text] [Related]
30. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
31. Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
Vigna E; Recchia AG; Cuzzola M; Morabito L; Gentile M; Morabito F
Leuk Lymphoma; 2014 Jun; 55(6):1408-9. PubMed ID: 23952245
[No Abstract] [Full Text] [Related]
32. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
Zago M; Adam P; Goldschmidt H; Fend F; Kanz L; Weisel K
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e7-e11. PubMed ID: 24169269
[No Abstract] [Full Text] [Related]
33. The evolving role of lenalidomide in non-Hodgkin lymphoma.
Galanina N; Petrich A; Nabhan C
Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.
Zagouri F; Kastritis E; Gavriatopoulou M; Sergentanis TN; Psaltopoulou T; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2014 Sep; 55(9):2018-23. PubMed ID: 24295131
[TBL] [Abstract][Full Text] [Related]
35. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M
Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme: A Multicenter Retrospective Cohort Study.
Roux C; Sbidian E; Bouaziz JD; Kottler D; Joly P; Descamps V; Prost C; Samimi M; Seneschal J; Dupin N; Girard C; Paul M; Le Cleach L; Ingen-Housz-Oro S
JAMA Dermatol; 2021 Dec; 157(12):1472-1476. PubMed ID: 34757396
[TBL] [Abstract][Full Text] [Related]
39. Intermittent oral cyclosporin for recurrent herpes simplex-associated erythema multiforme.
Bakis S; Zagarella S
Australas J Dermatol; 2005 Feb; 46(1):18-20. PubMed ID: 15670172
[TBL] [Abstract][Full Text] [Related]
40. A review of the history, properties, and use of the immunomodulatory compound lenalidomide.
Zeldis JB; Knight R; Hussein M; Chopra R; Muller G
Ann N Y Acad Sci; 2011 Mar; 1222():76-82. PubMed ID: 21434945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
